Lyell Immunopharma, Inc. Debt Securities, Available-for-sale, Amortized Cost
Lyell Immunopharma, Inc. (LYEL) had Debt Securities, Available-for-sale, Amortized Cost of $216.05 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $216.05M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $244.26M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $236.56M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $304.45M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $216.05M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $244.26M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $236.56M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $304.45M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $280.70M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $307.95M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $358.26M 10-K · filed 2026-03-12 |
| 2024-09-30 | $438.38M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $477.64M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $501.51M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $544.88M 10-K · filed 2025-03-11 |
| 2021-09-30 | $915.84M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $955.71M 10-Q · filed 2021-08-12 |
| 2020-12-31 | $669.83M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |